<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04769440</url>
  </required_header>
  <id_info>
    <org_study_id>FMASU R 07/2021</org_study_id>
    <nct_id>NCT04769440</nct_id>
  </id_info>
  <brief_title>Effect of mgso4 on Oxygenation and Lung Mechanics in Morbidly Obese Patients During Bariatric Surgery</brief_title>
  <official_title>Effect of MgSo4 Infusion on Oxygenation and Lung Mechanics in Morbidly Obese Patients Undergoing Bariatric Surgery.A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to study the effect of mgso4 infusion on oxygenation and lung&#xD;
      mechanics in morbidly obese patients undergoing bariatric surgery&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background and objectives: morbidly obese patients are characterized by a high prevalence of&#xD;
      restrictive lung disease. Respiratory mechanics are significantly altered in obesity. These&#xD;
      changes are exacerbated with general anesthesia .Obesity also results in reduced lung and&#xD;
      chest wall compliance ,increased lung resistance ,reduced oxygenation.MgSo4 is promising in&#xD;
      managing several respiratory disorders.it cause smooth muscle relaxation and reduce airflow&#xD;
      obstruction.&#xD;
&#xD;
      The objective of this trial is to study the effect of mgso4 infusion on oxygenation and lung&#xD;
      mechanics in morbidly obese patients undergoing bariatric surgery.&#xD;
&#xD;
      the following will be recorded :intraoperative oxygenation,lung&#xD;
      mechanics,MAP,HR,EtCO2,plateau and peak airway pressure,sedation score,serum mgso4&#xD;
      level,change in P/F ratio and dynamic lung compliance,respiratory rate postoperative&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2021</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pao2</measure>
    <time_frame>5 minutes after intubation to 90 minutes after starting drug infusion</time_frame>
    <description>arterial oxygenation during surgery determined by Pao2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pao2/FIO2</measure>
    <time_frame>5 minutes after intubation to 90 minutes after starting drug infusion</time_frame>
    <description>arterial oxygenation during surgery determined by Pao2/FIO2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Static lung compliance</measure>
    <time_frame>5 minutes after intubation to 90 minutes after starting drug infusion</time_frame>
    <description>will be calculated as:tidal volume/(plateau pressure-positive end expiratory pressure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mg sulphate level</measure>
    <time_frame>One hour postoperatively</time_frame>
    <description>serum mgso4 level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dead space</measure>
    <time_frame>5 minutes after intubation to 90 minutes after starting drug infusion</time_frame>
    <description>dead space will be calculated as : Vd/Vt</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamic lung compliance</measure>
    <time_frame>5 minutes after intubation to 90 minutes after starting drug infusion</time_frame>
    <description>will be calculated as :tidal volume/(peak airway pressure-positive end expiratory pressure)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>M group (Mg sulphate )</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will receive 30mg/kg LBW of 10%mgso4 in 100 ml normal saline intravenously over 30 minutes as a loading dose ,followed by 10 mg /kg LBW for 90 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C group (control )</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients will receive 100 ml of normal saline intravenously over 30 minutes followed by saline infusion for 90 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mg sulphate</intervention_name>
    <description>mgso4 infusion will start 15 minutes after intubation , 30 mg/kg LBW of 10%mgso4 in 100 ml normal saline I.V ,over 30 minutes followed by 10 mg/kg LBW for 90 minutes</description>
    <arm_group_label>M group (Mg sulphate )</arm_group_label>
    <other_name>mgso4</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients age between 21-60 years.&#xD;
&#xD;
          -  BMI more than 40kg/m2&#xD;
&#xD;
          -  Patients with restrictive lung disease(FVC&gt;70%)&#xD;
&#xD;
          -  American society of Anesthesiologists(ASA) physical status II&#xD;
&#xD;
          -  No previous abdominal surgery&#xD;
&#xD;
          -  Scheduled for laparoscopic bariatric surgery not exceeding 3 hours.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient refusal to participate in the study&#xD;
&#xD;
          -  ASA physical status more than II&#xD;
&#xD;
          -  patients with heart failure&#xD;
&#xD;
          -  Kidney disease&#xD;
&#xD;
          -  Patients on antiarrhythmic drugs&#xD;
&#xD;
          -  Patients taking beta or calcium channel blockers&#xD;
&#xD;
          -  Allergy to study drugs&#xD;
&#xD;
          -  Patients with combined restrictive-obstructive lung disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marwa M Mowafi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marwa M Mowafi, MD</last_name>
    <phone>01001320734</phone>
    <phone_ext>002</phone_ext>
    <email>drmarwamostafa@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rasha G Abusinna, MD</last_name>
    <phone>01117179870</phone>
    <phone_ext>002</phone_ext>
    <email>rashagamalabusinna@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ain Shams University Hospital</name>
      <address>
        <city>Cairo</city>
        <state>Abassia</state>
        <zip>11591</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>Marwa M Mowafi, MD</last_name>
      <phone>01001320734</phone>
      <phone_ext>002</phone_ext>
      <email>drmarwamostafa@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Rasha G Abusinna, MD</last_name>
      <phone>01117179870</phone>
      <phone_ext>002</phone_ext>
      <email>rashagamalabusinna@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 14, 2021</study_first_submitted>
  <study_first_submitted_qc>February 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2021</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Marwa Mostafa Mohamed Ali Mowafi</investigator_full_name>
    <investigator_title>Lecturer of anesthesia ,principal Investigator</investigator_title>
  </responsible_party>
  <keyword>mgso4</keyword>
  <keyword>oxygenation</keyword>
  <keyword>lung mechanics</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

